Paper
A Novel Anti-Inflammatory Role of Simvastatin in a Murine Model of Allergic Asthma1
Published Mar 1, 2004 · A. Mckay, B. Leung, I. McInnes
The Journal of Immunology
206
Citations
6
Influential Citations
Abstract
Statins, the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, are effective serum cholesterol-lowering agents in clinical practice, and they may also have anti-inflammatory properties. Asthma is characterized by chronic eosinophilic inflammation in the airways, which is thought to be regulated by the activity of T lymphocytes. We therefore examined the anti-inflammatory activity of simvastatin in a murine model of allergic asthma. In mice previously sensitized to OVA, simvastatin treatment, either orally or i.p., reduced the total inflammatory cell infiltrate and eosinophilia in bronchoalveolar lavage fluid in response to inhaled OVA challenge. Simvastatin therapy i.p. was also associated with a reduction in IL-4 and IL-5 levels in bronchoalveolar lavage fluid and, at higher doses, a histological reduction in inflammatory infiltrates in the lungs. OVA-induced IL-4, IL-5, IL-6, and IFN-γ secretion was reduced in thoracic lymph node cultures from simvastatin-treated mice. Simvastatin treatment did not alter serum total IgE or OVA-specific IgG1 and IgG2a levels. These data demonstrate the therapeutic potential of statin-sensitive pathways in allergic airways disease.
Non-RCT
Animal Study
Highly CitedSimvastatin treatment reduces inflammation in the airways of mice with allergic asthma, demonstrating the potential therapeutic potential of statin-sensitive pathways in allergic airways disease.
Full text analysis coming soon...